Terms: = Bone cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Treatment
80 results:
1. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency treatment Consortium (PIDTC) landmark study.
Eissa H; Thakar MS; Shah AJ; Logan BR; Griffith LM; Dong H; Parrott RE; O'Reilly RJ; Dara J; Kapoor N; Forbes Satter L; Chandra S; Kapadia M; Chandrakasan S; Knutsen A; Jyonouchi SC; Molinari L; Rayes A; Ebens CL; Teira P; Dávila Saldaña BJ; Burroughs LM; Chaudhury S; Chellapandian D; Gillio AP; Goldman F; Malech HL; DeSantes K; Cuvelier GDE; Rozmus J; Quinones R; Yu LC; Broglie L; Aquino V; Shereck E; Moore TB; Vander Lugt MT; Mousallem TI; Oved JH; Dorsey M; Abdel-Azim H; Martinez C; Bleesing JH; Prockop S; Kohn DB; Bednarski JJ; Leiding J; Marsh RA; Torgerson T; Notarangelo LD; Pai SY; Pulsipher MA; Puck JM; Dvorak CC; Haddad E; Buckley RH; Cowan MJ; Heimall J
J Allergy Clin Immunol; 2024 Jan; 153(1):287-296. PubMed ID: 37793572
[TBL] [Abstract] [Full Text] [Related]
2. A phase I/II study of the safety and efficacy of [
Wild D; Grønbæk H; Navalkissoor S; Haug A; Nicolas GP; Pais B; Ansquer C; Beauregard JM; McEwan A; Lassmann M; Pennestri D; Volteau M; Lenzo NP; Hicks RJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):183-195. PubMed ID: 37721581
[TBL] [Abstract] [Full Text] [Related]
3. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract] [Full Text] [Related]
4. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Behrouzi R; Armstrong AC; Howell SJ
Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881
[TBL] [Abstract] [Full Text] [Related]
5. Lung cancer with breast metastasis: a case report and review of the literature.
Cao X; Chen P; Agyekum EA; Zhang Q; Qian X; Wu T; Chambers KH; Yin L
J Int Med Res; 2023 Jul; 51(7):3000605231188287. PubMed ID: 37523488
[TBL] [Abstract] [Full Text] [Related]
6. Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.
Bender L; Pflumio C; Trensz P; Pierard L; Kalish M; Fischbach C; Petit T
Cancer Treat Res Commun; 2023; 36():100738. PubMed ID: 37390791
[TBL] [Abstract] [Full Text] [Related]
7. Primary Ewing sarcoma of the lung: A systematic review of the recent literature.
Fedeli MA; Marras V; Fara AM; Deiana A; Lobrano R; Cossu A; Paliogiannis P
Ann Diagn Pathol; 2023 Aug; 65():152152. PubMed ID: 37149954
[TBL] [Abstract] [Full Text] [Related]
8. Plasma hPG
Prieur A; Harper A; Khan M; Vire B; Joubert D; Payen L; Kopciuk K
BMC Cancer; 2023 Apr; 23(1):305. PubMed ID: 37016331
[TBL] [Abstract] [Full Text] [Related]
9. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney cancer Consortium (TKCC) Database.
Yekedüz E; Karakaya S; Ertürk İ; Tural D; Uçar G; Şentürk Öztaş N; Arıkan R; Hızal M; Küçükarda A; Sever ÖN; Arslan Ç; Can O; Kılıçkap S; Yazgan C; Karadurmuş N; Şendur MA; Çiçin İ; Demirci U; Özgüroğlu M; Öksüzoğlu B; Ürün Y
Clin Genitourin Cancer; 2023 Feb; 21(1):175-182. PubMed ID: 35970759
[TBL] [Abstract] [Full Text] [Related]
10. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
[TBL] [Abstract] [Full Text] [Related]
11. Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation.
Kroesen M; Miladinovic V; Hutschemaekers SAJ; Jacobs J; van der Vos C; Wolf AL; Hoogeman MS; van Vulpen M; Bloem JL; P D S Dijkstra S; Peul WC; Penninkhof JJ; Krol ADG
Radiother Oncol; 2022 Jan; 166():58-64. PubMed ID: 34843840
[TBL] [Abstract] [Full Text] [Related]
12. Skull Base Tumors: Neuropathology and Clinical Implications.
Bi WL; Santagata S
Neurosurgery; 2022 Mar; 90(3):243-261. PubMed ID: 34164689
[TBL] [Abstract] [Full Text] [Related]
13. The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis.
Funasaka C; Naito Y; Kusuhara S; Nakao T; Fukasawa Y; Mamishin K; Komuro A; Okunaka M; Kondoh C; Harano K; Kogawa T; Matsubara N; Hosono A; Kawasaki T; Mukohara T
Breast; 2021 Aug; 58():50-56. PubMed ID: 33901922
[TBL] [Abstract] [Full Text] [Related]
14. Which is the optimal minimally invasive treatment for osteoid osteoma of the hip? A systematic review and proportional meta-analysis.
Efthymiadis A; Tsikopoulos K; Uddin F; Kitridis D; Edwards N; Sidiropoulos K; Lavalette D
J Orthop Sci; 2022 Mar; 27(2):456-462. PubMed ID: 33563522
[TBL] [Abstract] [Full Text] [Related]
15. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.
Gu ZB; Liao LM; Yao GJ; Fang M; Huang L
Curr Probl Cancer; 2021 Oct; 45(5):100702. PubMed ID: 33454089
[TBL] [Abstract] [Full Text] [Related]
16. Does a Custom Electronic Health Record Alert System Improve Physician Compliance With National Quality Measures for Palliative bone Metastasis Radiotherapy?
Grant SR; Smith BD; Pandey P; Maldonado JA; Kim M; Moon BS; Colbert LE
JCO Clin Cancer Inform; 2021 Jan; 5():36-44. PubMed ID: 33411621
[TBL] [Abstract] [Full Text] [Related]
17. A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.
Fusco V; Cabras M; Erovigni F; Dell'Acqua A; Arduino PG; Pentenero M; Appendino P; Basano L; Ferrera FD; Fasciolo A; Caka M; Migliario M
Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e466-e473. PubMed ID: 33340073
[TBL] [Abstract] [Full Text] [Related]
18. [Sinonasal renal cell-like adenocarcinoma: a clinicopathological analysis of five cases].
Yuan CC; Zhai CW; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1147-1151. PubMed ID: 33152820
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting.
KovaČ A; Matos E; Kuhar CG; Čakš M; Ovčariček T; Mencinger M; Humar M; Borštnar S
Cancer Treat Res Commun; 2020; 25():100201. PubMed ID: 32979704
[TBL] [Abstract] [Full Text] [Related]
20. Tumor-Treating Fields Inhibit the Metastatic Potential of Osteosarcoma Cells.
Oh JY; Lee YJ; Kim EH
Technol Cancer Res Treat; 2020; 19():1533033820947481. PubMed ID: 32938326
[TBL] [Abstract] [Full Text] [Related]
[Next]
